Skip to content
Adrienne Monson – Lifestyle
Author:
Celcuity Inc.
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
May 1, 2026
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
March 18, 2026
←
Previous Page
1
2
3